Viveon Health Acquisition Corp.
VHAQ-WT
New York Stock Exchange Arca0.01
USD
-0.01
- -
CIK
0001823857
Return %
Stock
S&P500
1Y
-85.00
26.53
3Y
-90.00
76.60
5Y
-90.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001823857
- Similar Companies
- Business
- Viveon Health Acquisition Corp. (VHAQ-WT) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting companies in the health care industry. It offers no specific products or services beyond its standard special purpose acquisition company structure, which includes public equity securities and warrants traded on the Nasdaq Capital Market under the ticker VHAQ-WT; the company focuses on identifying and consummating an initial business combination with a target in healthcare sectors such as biotechnology, medical devices, diagnostics, therapeutics, or health tech services. Founded in 2023 and headquartered in New York, New York, Viveon Health Acquisition Corp. operates principally in the United States, with potential targets across North America and select international markets. In late 2024, the company underwent a significant strategic shift through its merger with Bluejay Diagnostics, Inc., a diagnostics firm developing microneedle-based blood collection devices and point-of-care testing platforms; post-merger, the combined entity began operating under the name Viveon Health, Inc., retaining Nasdaq listing under VHAQ (common shares) and VHAQ-WT (warrants). This transaction marked its de-SPAC completion, with no additional major funding rounds or acquisitions reported in 2025; operational focus shifted to advancing Bluejay's portfolio, including the ADEXUS-A1 platform for rapid biomarker detection. No recent partnerships, name changes beyond the merger rebranding, or new product launches have been publicly announced as of December 2025.